Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference
Company Presentation on June 1, 2015 at 2:00 PM Pacific Time/5:00 PM Eastern Time
NEW YORK, May 27, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 LD Micro Invitational Conference on Monday, June 1, 2015 at the Luxe Sunset Hotel in Bel Air, California.
The presentation by Michael Becker, Relmada's senior vice president of finance and corporate development, is scheduled to begin at 2:00 p.m. PT/5:00 p.m. ET. A live webcast of the presentation will be available through the Company's website at www.relmada.com. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.
Members of the investment community who are interested in meeting with Relmada's management team during the conference event should contact Christine Silverstein, director of investor relations at Relmada Therapeutics, at (212) 702-7167 or firstname.lastname@example.org.
About LD MICRO
LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Main Event in December. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.
This news release contains "forward-looking statements." These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Berry & Company Public Relations
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-the-2015-ld-micro-invitational-conference-300089049.html
SOURCE Relmada Therapeutics, Inc.
Released May 27, 2015